Depo-Provera MDL update: the court schedule changed, but the records still matter

Depo-Provera MDL update: the court schedule changed, but the records
still matter

If you used Depo-Provera and later learned you had a meningioma, the
first question is usually not legal. It is practical: what do I
still have, who gave me the shots, and what did the scan actually
show?

That is where the Depo-Provera litigation sits right now. The
federal cases are centralized in MDL No. 3140 in the Northern
District of Florida. The court's MDL page says the cases share
allegations that Depo-Provera, or generic depot medroxyprogesterone
acetate, can cause users to develop one or more meningiomas. The
defendants deny the allegations and maintain that the medication is
safe and effective.

What changed in the Depo-Provera MDL schedule?

The court's current public MDL page lists case management
conferences through the rest of 2026 and a Rule 702 motions hearing
for September 18, 2026, after that day's case management conference.
Rule 702 is the federal evidence rule courts use when deciding
whether expert testimony is reliable enough to be heard by a jury.

Earlier litigation calendars had focused attention on summer expert
hearings and a first bellwether window later in 2026. The public
schedule now points readers to the master docket, Case No.
3:25-md-3140, for the full record and lists the September 18 Rule
702 hearing date. For families watching from the outside, the point
is simple: the science fight has not disappeared. The dates and
procedural posture can change quickly.

A bellwether trial, if and when one is reset, would not decide every
person's claim. It would test evidence in a small number of cases
and give both sides more information about how juries may respond.

Why meningioma claims are being filed

Meningiomas are tumors that arise from the membranes around the
brain and spinal cord. Many are benign, but "benign" can be a
misleading word when a tumor is pressing on vision, hearing,
balance, or other brain structures. Some people need monitoring.
Others need surgery, radiation, or repeat treatment.

The medical issue in these cases centers on long-term exposure to
medroxyprogesterone acetate, the active drug in Depo-Provera. A 2024
BMJ national case-control study using French health system data
reported an increased risk of intracranial meningioma requiring
surgery among people with prolonged exposure to injectable
medroxyprogesterone acetate. New Zealand's Medsafe summarized the
same study in March 2025 and said the absolute risk remained low,
while also noting that the Depo-Provera and Provera data sheets were
updated to warn that meningioma has been reported with long-term use
and to discontinue the medicine if meningioma occurs.

Pfizer's current U.S. prescribing information for Depo-Provera CI
now lists "Warnings and Precautions, Meningioma" as a recent major
change, revised in December 2025. The label also continues to state
that Depo-Provera CI is not recommended as a long-term birth control
method, meaning longer than two years, unless other options are
considered inadequate.

Those facts do not prove any one case. They do explain why
plaintiffs are focusing on duration of use, tumor diagnosis,
warnings, and what doctors and patients were told at the time.

What potential claimants should gather first

A Depo-Provera meningioma review usually starts with documents, not
speculation. The most useful records often include:

• Pharmacy records, OB-GYN records, injection logs, or clinic notes showing Depo-Provera shots
• Dates of first and last use, including gaps in treatment
• MRI, CT, neurology, neurosurgery, oncology, or radiation records showing a meningioma diagnosis
• Operative reports, pathology reports, radiation plans, and follow-up imaging when treatment occurred
• Notes showing symptoms before diagnosis, such as headaches, vision changes, hearing problems, seizures, dizziness, or balance issues
• Records of any prior meningioma history before Depo-Provera use

Do not worry if the records are incomplete. Many people do not have
every injection date in a folder at home. Pharmacies, clinics,
hospital portals, and insurance records may fill in the missing
pieces.

Questions worth asking before you sign anything

If a law firm reviews your claim, ask what proof of use they need,
what medical records they will request, and whether they are
evaluating brand-name Depo-Provera, generic depot
medroxyprogesterone acetate, or both. Also ask how they handle cases
where the person used Depo-Provera for contraception years before
the tumor was found.

You should not be promised a settlement amount. Public litigation
updates can describe schedules, case counts, studies, and
allegations. They cannot tell you what your individual claim is
worth without medical records, exposure proof, and a careful look at
causation issues.

The bottom line

The Depo-Provera MDL is active, and the court's public schedule now
highlights a September 18, 2026 Rule 702 hearing. The important
claimant question has not changed: can the person show Depo-Provera
exposure and a later meningioma diagnosis with real records?

If you or a family member used Depo-Provera and later received a
meningioma diagnosis, it may be worth getting the timeline organized
now. Dates, imaging reports, and injection records matter more than
memories.

This article is attorney advertising and is for informational
purposes only. It is not medical advice and does not create an
attorney-client relationship. Talk with your doctor before changing
or stopping any medication, and speak with a qualified attorney
about your specific legal rights.

Sources checked: U.S. District Court for the Northern District of Florida MDL No. 3140 page; Pfizer Depo-Provera CI prescribing information revised December 2025; Medsafe March 2025 Prescriber Update on medroxyprogesterone acetate and meningioma; BMJ 2024 national case-control study on progestogens and intracranial meningioma; Lawsuit Information Center July 2026 Depo-Provera litigation update.